ZA893259B - Use and agent for reducing the side effects of tnf - Google Patents

Use and agent for reducing the side effects of tnf

Info

Publication number
ZA893259B
ZA893259B ZA893259A ZA893259A ZA893259B ZA 893259 B ZA893259 B ZA 893259B ZA 893259 A ZA893259 A ZA 893259A ZA 893259 A ZA893259 A ZA 893259A ZA 893259 B ZA893259 B ZA 893259B
Authority
ZA
South Africa
Prior art keywords
side effects
tnf
agent
reducing
tnfs
Prior art date
Application number
ZA893259A
Inventor
Hubert Dr Heuer
Heuer Dr Hubert
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of ZA893259B publication Critical patent/ZA893259B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Paper (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
  • Separation Of Suspended Particles By Flocculating Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Concomitant administration of TNFs with a PAF antagonist allows the unwanted side effects of the TNFs to be reduced and the therapeutic index of the TNFs to be increased.
ZA893259A 1988-05-11 1989-05-03 Use and agent for reducing the side effects of tnf ZA893259B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3816169A DE3816169A1 (en) 1988-05-11 1988-05-11 USE AND AGENT FOR REDUCING THE SIDE EFFECTS OF TNF

Publications (1)

Publication Number Publication Date
ZA893259B true ZA893259B (en) 1991-01-30

Family

ID=6354207

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA893259A ZA893259B (en) 1988-05-11 1989-05-03 Use and agent for reducing the side effects of tnf

Country Status (13)

Country Link
EP (1) EP0341558B1 (en)
JP (1) JP2709139B2 (en)
KR (1) KR900017592A (en)
AT (1) ATE78695T1 (en)
AU (1) AU614607B2 (en)
CA (1) CA1336825C (en)
DE (2) DE3816169A1 (en)
DK (1) DK220789A (en)
ES (1) ES2042864T3 (en)
GR (1) GR3005387T3 (en)
HU (1) HUT52381A (en)
IL (1) IL90206A0 (en)
ZA (1) ZA893259B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3735525C2 (en) * 1987-10-20 1997-02-20 Korth Ruth Maria Method for determining the efficacy of paf-acether receptor antagonists
GB8926611D0 (en) * 1989-11-24 1990-01-17 Xenova Ltd Compound and its use

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988002632A1 (en) * 1986-10-16 1988-04-21 President And Fellows Of Harvard College Combinations of tumor necrosis factors and anti-inflammatory agents and methods for treating malignant and non-malignant diseases

Also Published As

Publication number Publication date
GR3005387T3 (en) 1993-05-24
DK220789A (en) 1989-11-12
DK220789D0 (en) 1989-05-05
AU614607B2 (en) 1991-09-05
JPH0276825A (en) 1990-03-16
IL90206A0 (en) 1989-12-15
HUT52381A (en) 1990-07-28
EP0341558A3 (en) 1990-05-09
AU3406489A (en) 1989-11-16
EP0341558B1 (en) 1992-07-29
DE3816169A1 (en) 1989-11-23
KR900017592A (en) 1990-12-19
CA1336825C (en) 1995-08-29
DE58901920D1 (en) 1992-09-03
JP2709139B2 (en) 1998-02-04
ATE78695T1 (en) 1992-08-15
EP0341558A2 (en) 1989-11-15
ES2042864T3 (en) 1993-12-16

Similar Documents

Publication Publication Date Title
AU4519089A (en) Device for aiding in preparation of intravenous therapy
GB8914598D0 (en) Niacin-containing composition and its therapeutic use
GB8812597D0 (en) Therapeutic agents
ZA898201B (en) Gestodene-containing agent for transdermal administration
MY103872A (en) 3-substituted-2-oxindole-1-carboxamides for suppressing t-cell function.
GB8816299D0 (en) Therapeutic agents
ZA893259B (en) Use and agent for reducing the side effects of tnf
TW263437B (en)
GB8407359D0 (en) Catheter for administering oxygen
GB8812596D0 (en) Therapeutic agents
GB8912373D0 (en) Medicament for various skin and ulcer disorders
GB8804016D0 (en) Therapeutic agents
ZA893261B (en) Synergistic combinations and their use as therapeutic agents
ZA888714B (en) Medicament with antiemetic action
IE883395L (en) Medicament with antiemetic action
IE870019L (en) Arrangement in injection syringe for use once only
GB8801759D0 (en) Therapeutic agents
GB8817311D0 (en) Therapeutic agents
GB8801758D0 (en) Therapeutic agents
GB8812145D0 (en) Therapeutic agents
CS631190A3 (en) E1 prostaglandin in injection medicinal form
GB8725220D0 (en) Therapeutic use
CS8802913A2 (en) Hyperthyroidism medicament
GB8810300D0 (en) Therapeutic agents
GB8801273D0 (en) Therapeutic agents